Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

CPIX stock opened at $1.97 on Friday. Cumberland Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $2.79. The business’s fifty day simple moving average is $1.87 and its two-hundred day simple moving average is $1.82. The firm has a market cap of $29.36 million, a price-to-earnings ratio of -11.59 and a beta of 0.18. The company has a quick ratio of 1.21, a current ratio of 1.53 and a debt-to-equity ratio of 0.36.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $10.09 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 8.68% and a negative net margin of 6.17%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Cumberland Pharmaceuticals during the fourth quarter valued at approximately $46,000. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals during the third quarter worth $142,000. B. Riley Wealth Advisors Inc. purchased a new stake in Cumberland Pharmaceuticals in the second quarter valued at $133,000. Acadian Asset Management LLC raised its position in Cumberland Pharmaceuticals by 27.8% in the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after purchasing an additional 40,949 shares during the period. Finally, Renaissance Technologies LLC raised its position in Cumberland Pharmaceuticals by 6.3% in the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after purchasing an additional 38,100 shares during the period. 16.70% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Read More

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.